In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Onux Medical

This article was originally published in The Gray Sheet

Executive Summary

Completion of $5 mil. second round financing Aug. 18 brings total funds raised since the firm's founding in 1998 to $9.5 mil., with contributions from initial investors Domain Associates and Delphi Ventures. The funds will help support the planned October launch of the Hampton, New Hampshire firm's 510(k)-cleared Touche Salute and Touche Grasper minimally invasive, needleless suturing technologies through distributors. The Salute is designed for use in hernia repair while the Grasper is intended for use in general and cardiac surgery. An international launch is planned by the second quarter of 2001. A portion of the funds also will support clinical trials in early 2001 for femoral artery closure and anastomosis indications, the firm says. "Trials for our femoral artery closure products and coronary artery bypass couplers will occur much quicker given these added resources," the firm says. The formation of a separate cardiovascular division in June "will allow us to focus specific energies on further development of our intellectual property in the exciting CV area," President and CEO Gregory Sancoff explains in a release

You may also be interested in...

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts